RecruitingGastric CancerDiabetes Mellitus, Type 2
Surgical TreAtment for Obesity Related Disease and Onco-Metabolic Surgery
Eligible age
20–69 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a prospective, multi-center, randomized controlled trial to compare Billroth II reconstruction versus conventional Roux-en-Y reconstruction versus long limb Roux-en-Y reconstruction for glycemic control in patients with concurrent type 2 diabetes and gastric cancer.
Sponsor: Korea University Anam Hospital
You may qualify if…
- ✓ Distal gastric adenocarcinoma diagnosed pathologically under preoperative endoscopic biopsy, and clinical stage I-II
- ✓ Body mass index ≥ 23 kg/m2
- ✓ Type 2 diabetes and HbA1c ≥ 6.5%
You may not qualify if…
- ✕ Insulin usage for glycemic control at the time of screening evaluation
- ✕ Prior gastrointestinal surgery including splenectomy, hepatobiliary and pancreatic surgery (except hemorrhoidectomy, herniorrhaphy, and appendectomy)
- ✕ Abdominal, thoracic, pelvic and/or obstetric-gynecologic surgery within 3 months
- ✕ Cardiovascular conditions including significant known CAD, uncompensated congestive heart failure, history of stroke, or uncontrolled hypertension. Subjects with CAD that have been successfully treated with CABG or PCI, and have no evidence of active ischemia are eligible
- ✕ Kidney disease including renovascular hypertension, renal artery stenosis, or end-stage renal disease
- ✕ Chronic liver disease including liver cirrhosis, alpha-1 antitrypsin deficiency
- ✕ Gastrointestinal disorders including inflammatory bowel disease (Crohn's disease or ulcerative colitis) or any malabsorptive disorders
- ✕ Psychiatric disorders including dementia, active psychosis, history of suicide attempts, alcohol or drug abuse within 12 months
Source: ClinicalTrials.gov · NCT04284943 · last updated 2026-08-07